

SJMLS - 10(1) - 038

Preparation of Plasma-based Medicinal Products in Combating Coagulation Factors Deficiencies by Apheresis Technique

Dunya, Y.*, Bukar, A., Obi, S.O., Medugu, J.T., Waziri, N.S., John, W.K., Mela, T.S., Halima, I., Azuike, C.G.

Department of Medical Laboratory Science, University of Maiduguri.

Author for Correspondence: dunyachiroma@gmail.com / +234-806-962-3879.

<https://dx.doi.org/10.4314/sokjmls.v10i1.38>

Summary

The production of plasma-based medicinal products is vital in the treatment and management of coagulation factor deficiencies, immune diseases, and various severe medical conditions. This study focuses on the preparation of plasma-based products using the apheresis technique, with a particular emphasis on ensuring the highest standards of safety and efficacy throughout the production process. The research outlines the comprehensive methods employed in plasma fractionation, particularly the cold ethanol method, which remains a cornerstone in modern plasma-derived product manufacturing. The fractionation process not only enables the extraction of critical therapeutic components such as albumin, immunoglobulin G (IgG), and coagulation factors VIII and IX, but also involves stringent safety measures to ensure the removal and inactivation of potential viral contaminants. The paper highlights the importance of adhering to regulatory frameworks governing the production and administration of these plasma-derived products, ensuring they remain among the safest and most reliable biological therapies available today. The study underscores the critical role these products play in the management of coagulation disorders and other related deficiencies, thus contributing significantly to public health.

Keywords: Plasma fractionation, apheresis, coagulation factors, cold ethanol method, plasma-based medicinal products, viral inactivation, regulatory compliance.

Introduction

The preparation of plasma-based medicinal products has been the cornerstone in the treatment of coagulation factor deficiencies and other blood disorders for decades. This field has evolved significantly since the 1940s when Cohn and Colleagues (1964) introduced the groundbreaking cold ethanol fractionation method, revolutionizing the separation of plasma into its various protein components. This innovation marked a pivotal shift from whole blood transfusions, which were widely used during World War II, to more targeted and efficient treatments (Heim *et al.*, 2009).

Plasma-derived medicinal products (PDMPs) have since become essential in modern healthcare, recognized by the World Health Organization (WHO) as crucial elements in their model list of essential medicines (WHO, 2021). These products, which include albumin, immunoglobulins, and coagulation factors, are vital in treating a range of serious health conditions, particularly coagulation factor deficiencies.

The apheresis technique, a key focus of this study, has further refined the process of plasma collection. This method allows for the selective extraction of plasma while returning other blood components to the donor, enabling more frequent donations and increasing the efficiency of plasma collection. When combined with advanced fractionation techniques, apheresis has significantly enhanced the production of PDMPs, improving both yield and purity.

The production of these life-saving products involves a complex interplay of scientific methodology and stringent regulatory oversight. From donor selection to final product formulation, each step is carefully controlled to ensure the highest standards of safety and efficacy. Particularly crucial are the advanced viral inactivation and removal processes, which mitigate the inherent risks associated with products derived from human donors (Dichtelmuller *et al.*, 2011).

As global demand for PDMPs continues to rise, ongoing research and development in plasma fractionation and related technologies remain essential. This paper explores the current state-of-the-art in the preparation of plasma-based medicinal products, with a specific focus on their role in combating coagulation factor deficiencies through the apheresis technique. By examining the intricate processes involved, from plasma collection to final product formulation, we aim to provide a comprehensive overview of this critical field in modern medicine. Our analysis encompasses the scientific, regulatory, and practical aspects of PDMP production, offering insights into current practices and future directions in this vital area of healthcare.

Methodology

Plasma Collection

Plasma collection through plasmapheresis remains the primary method for obtaining large volumes of plasma efficiently. Recent advancements in apheresis technology have further improved the process. For instance, the introduction of automated, multi-component collection devices allows for simultaneous collection of plasma and other blood components, optimizing donor time and resource utilization (Burgstaler, 2019). These systems can now collect up to 880 mL of plasma in a single session, a significant increase from the previous 600-800 mL range (Schreiber *et al.*, 2018).

Moreover, there's growing interest in pathogen reduction technologies (PRT) applied at the collection stage. The INTERCEPT Blood System for plasma, which uses amotosalen and UVA light, has shown promise in reducing the risk of transfusion-transmitted infections (Irsch and Lin, 2021).

Donor Selection and Screening

Recent updates in donor selection and screening protocols have incorporated new criteria to address emerging infectious diseases. For example, in response to the COVID-19 pandemic, additional screening measures and temporary deferral periods for donors with potential exposure to SARS-CoV-2 have been implemented (Pagano *et al.*, 2020).

Advancements in nucleic acid testing (NAT) technologies have improved the detection of viral contaminants. Multiplex NAT assays now allow for simultaneous detection of multiple pathogens, including emerging threats like Zika virus, with increased sensitivity and reduced window periods (Stramer *et al.*, 2019).

Plasma Fractionation

While the cold ethanol fractionation method remains foundational, significant advancements have been made in chromatographic techniques. The implementation of continuous chromatography systems, such as simulated moving bed chromatography, has improved process efficiency and product yield (Jungbauer and Göbel, 2018).

Membrane-based separation techniques are also gaining traction. For instance, the use of high-performance tangential flow filtration (HPTFF) has shown promise in improving the purity and yield of specific plasma proteins (Grilo *et al.*, 2017).

Viral Inactivation and Removal

Recent developments in viral inactivation methods include the use of ultraviolet C (UVC) light in combination with riboflavin. This method has shown effectiveness against a wide range of pathogens, including non-enveloped viruses, while maintaining protein functionality (Seltsam and Müller, 2018).

Nanofiltration techniques have also evolved, with the introduction of filters capable of removing smaller viruses without compromising product quality. For instance, filters with a pore size of 15-20 nanometers have demonstrated effective removal of parvovirus and other small non-enveloped viruses (Bräutigam *et al.*, 2020).

Quality Control and Testing

Advancements in analytical techniques have enhanced quality control measures. The implementation of high-resolution mass spectrometry allows for more precise characterization of plasma proteins and potential contaminants (Zhang *et al.*, 2020).

Real-time monitoring systems and process analytical technology (PAT) are being increasingly integrated into manufacturing processes. These systems provide continuous data on critical process parameters, allowing for rapid adjustments and improved consistency in product quality (Read *et al.*, 2018).

Regulatory Compliance and Documentation

Regulatory frameworks continue to evolve to address new challenges and technologies. The European Medicines Agency (EMA) has updated its guidelines on plasma-derived medicinal products, emphasizing the importance of a comprehensive quality management system throughout the manufacturing process (EMA, 2021).

The implementation of electronic systems for maintaining the Plasma Master File (ePMF) has improved data management and accessibility for regulatory authorities (Seitz *et al.*, 2019).

Documentation and Record-Keeping

The adoption of block chain technology in the pharmaceutical industry has potential applications in plasma product manufacturing. This technology could enhance traceability, from donor to final product, ensuring data integrity and facilitating rapid response to potential safety issues (Mackey *et al.*, 2019).

Advanced data analytics and machine learning algorithms are being explored to improve process understanding and predictive capabilities in plasma fractionation (Rathore *et al.*, 2020).

Safety and Risk Management

Recent focus has been on developing strategies to mitigate the risk of emerging pathogens. The implementation of rapid response protocols for emerging infectious diseases, as demonstrated during the COVID-19 pandemic, has become a crucial aspect of risk management (Di Minno *et al.*, 2020).

Pharmacovigilance systems have been enhanced to improve post-market surveillance of plasma-derived products. This includes the use of real-world evidence and patient registries to monitor long-term safety and efficacy (Peyvandi *et al.*, 2019).

Table 1: Role of Plasma Derived Products in Combating coagulation Factors Deficiencies.

Plasma	
Component	Clinical Use
Albumin	Shock, Burns, Hypoalbuminemia, Loss of blood
IgG	Passive Prophylaxis, Immune deficiency disorder, Immune thrombocytopenic purpura
Factor VIII	Haemophilia A
Factor IX	
Complex	Haemophilia B, Factor II and Factor X deficiencies
a1-antitrypsin	Hereditary deficiencies
Anti-thrombin III	Congenital deficiency

Table 2: Legal Basis: Special Regulations for Medicinal Products Derived from Human Blood or Human Plasma, in Addition to General Regulations for Biological Medicinal Products.

Aspect	Regulation	Description
General Regulations	Directive 2001/83/EC	Sets the foundation for all medicinal products, including those derived from human plasma.
Specific Regulations	Plasma Master File (PMF) System (EMA/CHMP/BWP/3794/03)	Provides guidelines for documenting plasma collection, fractionation, and testing procedures.
Additional Requirements	Annual Updates	Regular updates to the PMF system are required to demonstrate batch-to-batch consistency and the absence of specific viral contaminants.
Additional Requirements	Competent Authority Approval	May require product sample submission for independent testing before market release to ensure adherence to European Pharmacopoeia standards.

Table 3: Special Regulations for Medicinal Products Derived from Human Blood or Human Plasma, in Addition to General Regulations for Biological Medicinal Products.

Parameter	Test Method	Importance
Ph	pH meter	Ensures optimal protein structure and functionality.
Temperature	Thermometer	Monitors critical processing steps.
Ethanol Concentration	Refractometer	Maintains proper protein precipitation during fractionation.
Protein Content	Spectrophotometer	Verifies desired protein yield.
Biological Activity (e.g. Clotting Factors)	Coagulation Factor Assays	Confirms the potency and therapeutic efficacy of the product.
Bacterial Counts	Microbiological Assays	Ensures absence of microbial contamination.
Endotoxin Levels	Limulus Amebocyte Lysate (LAL) Assay	Detects bacterial endotoxins that can cause fever or inflammatory reactions.
Immunochemical Methods	Specific Assays (e.g. ELISA)	Quantifies immunoglobulins and verifies their functionality.

Table 4: A Comprehensive List of the General Methods

Method Code	Method Name	Description
2.6.20	Anti-A and anti-B haemagglutinins (indirect method)	Detects the presence of red blood cell antigens A and B.
2.6.21	Nucleic Acid Amplification Techniques	Detects and amplifies specific DNA or RNA sequences, used for viral detection.
2.6.22	Activated coagulation factors	Measures the activity of various coagulation factors involved in blood clotting.
2.6.26	Test for anti-D antibodies in human immunoglobulin for intravenous administration	Detects antibodies against the D antigen in Rh-negative individuals.
2.6.15	Prekallikrein activator	Measures the activity of an enzyme involved in the blood clotting cascade.
2.6.17	Test for anticomplementary activity of immunoglobulin	Assesses the ability of immunoglobulins to activate the complement system.
2.7.1	Immunochemical methods	Quantifies and characterizes proteins using techniques like ELISA or Western blotting.
2.7.4	Assay of human coagulation factor VIII	Measures the activity of factor VIII, essential for blood clotting.
2.7.9	Test for Fc function of immunoglobulin	Evaluates the ability of immunoglobulins to bind to cellular receptors.
2.7.10	Assay of human coagulation factor VII	Measures the activity of factor VII, involved in the initiation of blood clotting.
2.7.11	Assay of human coagulation factor IX	Measures the activity of factor IX, another key factor in blood clotting.
2.7.13	Assay of human anti-D immunoglobulin	Quantifies the amount of anti-D antibodies in Rh-negative individuals.

Conclusion and Recommendations

Plasma-based medicinal products (PDMPs) have emerged as indispensable tools in modern healthcare, addressing critical medical conditions such as coagulation factor deficiencies and immune disorders. The evolution of plasma fractionation techniques, coupled with stringent regulatory oversight and advancements in biotechnology, has

significantly enhanced the safety, efficacy, and accessibility of these products. PDMPs continue to play a pivotal role in treating a wide range of diseases, including hemophilia, immune deficiencies, and emerging infectious diseases like COVID-19. As global demand for these products grows, ongoing research and development are crucial to ensure their continued effectiveness and availability.

To further improve the field of plasma-based medicinal products, the following recommendations are proposed:

- Optimize plasma collection practices: Expand donor recruitment efforts, improve donor retention strategies, and invest in advanced technology to maximize efficiency and safety.
- Investment in advanced fractionation technologies: Explore and adopt newer fractionation methods like expanded bed adsorption chromatography to enhance product yield, purity, and safety.
- Strengthen viral inactivation and detection: Integrate cutting-edge technologies like UV light treatment with riboflavin and sensitive NAATs to minimize the risk of viral contamination.
- Promote ethical and sustainable plasma donation: Prioritize ethical considerations and sustainability in plasma donation, ensuring donor rights are respected and voluntary, non-remunerated donations are encouraged where feasible.
- Support recombinant therapies and gene therapy research: Explore alternative treatment options to reduce reliance on plasma donations and potentially provide more consistent and effective treatments.
- Expand clinical applications: Research and investigate new clinical applications of PDMPs to address emerging medical needs and expand their therapeutic potential.
- Harmonize regulatory standards globally: Work towards harmonizing regulatory standards for PDMPs across different regions to facilitate the exchange of plasma and products worldwide, ensuring equitable access to safe and effective therapies.

By implementing these recommendations, the field of plasma-based medicinal products can continue to evolve and provide life-saving therapies to patients worldwide.

References

- Bräutigam, S., *et al.* (2020). Virus clearance by filtration: Points to consider. *Biologicals*; **67**: 59-67.
- Burgstaler, J.E. (2019). Current safety and efficacy issues in therapeutic apheresis. *Journal of Clinical Apheresis*; **34**(1): 6-11.
- Cohn, E. J., Strong, E. L., Hughes, W. L., Mulford, D. J., Ashworth, J. N., Melin, M., & Taylor, H. L. (1946). Preparation and properties of serum and plasma proteins: A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. *Journal of the American Chemical Society*; **72**(11): 459-475.
- Di Minno, G., *et al.* (2020). Challenges in the Treatment of Haemophilia in the Era of COVID-19: A Multidisciplinary Perspective. *Blood Reviews*; **43**: 100743.
- Dichtelmuller, H. O., Biesert, L., Fabbrizi, F., Falbo, A., Flechsig, E., Groner, A., & Kempf, C. (2011). Contribution to safety of immunoglobulin and albumin from virus partitioning and inactivation by cold ethanol fractionation: A data collection from Plasma Protein Therapeutics Association member companies. *Transfusion*; **51**(7): 1412-1430.
- Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. *Official Journal of the European Union*; **311**: 67-128.
- European Medicines Agency (EMA). (2021). Guideline on plasma-derived medicinal products. EMA/CHMP/BWP/706271/2010 Rev.2.
- European Medicines Agency (EMA). (2003). Guideline on the scientific data requirements for a plasma master file (EMA/CHMP/BWP/3794/03).
- Garcia-Martinez, R., Caraceni, P., Bernardi, M., Gines, P., Arroyo, V., & Jalan, R. (2013). Albumin: Pathophysiologic basis of its role in the treatment of cirrhosis and its complications. *Hepatology*; **58**(5): 1836-1846.
- Grilo, A. L., *et al.* (2017). Advances in membrane chromatography for the capture step of human antibody purification. *Journal of Membrane Science*; **523**: 606-621.
- Heim, M. U., Meyer, B., & Hellstern, P. (2009). Recommendations for the use of therapeutic plasma. *Current Vascular Pharmacology*; **7**(2): 110-119.
- Irsch, J., & Lin, L. (2021). Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. *Transfusion Medicine and Hemotherapy*; **48**(2): 79-93.
- Joyner, M. J., Senefeld, J. W., Klassen, S. A., Mills, J. R., Johnson, P. W., Theel, E. S., ... &

- Wright, R. S. (2020). Evidence favouring the efficacy of convalescent plasma for COVID-19 therapy. *Clinical Medicine*; **26**: 100342.
- Jungbauer, A., & Göbel, U. (2018). Continuous downstream processing of biopharmaceuticals. *Biotechnology Journal*; **13**(3): 1700011.
- Kamran, M. H., & Mehran, G. (2016). Implementation of plasma fractionation in biological medicines production. *Iranian Journal of Biotechnology*; **14**(4): e1401.
- Lihme, A., Hansen, M. B., Andersen, M. B., & Burnouf, T. (2010). A novel core fractionation process of human plasma by expanded bed adsorption chromatography. *Analytical Biochemistry*; **399**(1): 102-109.
- Mackey, T. K., et al. (2019). 'Fit-for-purpose' challenges and opportunities for applications of blockchain technology in the future of healthcare. *BMC Medicine*; **17**(1): 68.
- Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. & Kay, M. A. (2020). Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. *Nature Medicine*; **12**(3): 342-347.
- Pagano, M. B., et al. (2020). Prepare to adapt: Blood supply and transfusion support during the first 2 weeks of the 2019 novel coronavirus (COVID-19) pandemic affecting Washington State. *Transfusion*; **60**(5): 908-911.
- Peyvandi, F., et al. (2019). Real-world experience in hemophilia B patients treated with factor IX products: Findings from the CHES II study. *Blood*; **134**(1): 2423.
- Plasma Protein Therapeutics Association (PPTA). (2021). Plasma donation and supply: Ethical considerations and sustainability. Retrieved from <http://www.pptaglobal.org>.
- Rathore, A. S., et al. (2020). Role of artificial intelligence and machine learning in downstream bioprocessing. *Bioengineering*; **7**(1): 26.
- Read, E. K., et al. (2018). Process analytical technology (PAT) for biopharmaceutical products: Part I. concepts and applications. *Biotechnology and Bioengineering*; **115**(2): 273-285.
- Schreiber, G. B., et al. (2018). Increasing the availability of plasma proteins for fractionation by more frequently allowing plasmapheresis volumes up to 880 mL. *Transfusion*; **58**(3): 781-789.
- Seitz, R., et al. (2019). The plasma master file concept and its implementation in the European Union. *Transfusion Medicine and Hemotherapy*; **46**(2): 137-145.
- Seltsam, A., & Müller, T. H. (2018). Pathogen inactivation of cellular blood products—An additional safety layer in transfusion medicine. *Transfusion Medicine and Hemotherapy*; **45**(5): 351-362.
- Stramer, S.L., Wend, U., Candotti, D., Foster, G.A., Hollinger, F.B., Dodd, R.Y., Allain, J.P., Gerlich, W. (2019). Nucleic acid testing to detect HBV, HCV, HIV and HTLV among blood donors: when, where and how. *International Society of Blood Transfusion Science Series*; **14**(1): 136-143.
- Traclet, J., Delaval, P., Terrioux, P., & Mornex, J. F. (2015). Augmentation therapy of alpha-1 antitrypsin deficiency associated emphysema. *Revue des Maladies Respiratoires*; **32**(4): 435-446.
- World Health Organization (WHO). (2021). Recommendations for the production, quality control, and regulation of plasma for fractionation. Retrieved from <http://www.who.int/bloodproducts>.
- Yong, K. W., Safwani, W. K. Z. W., Xu, F., & Pinguang-Murphy, B. (2020). Ultraviolet and riboflavin-mediated virus inactivation: A potential approach for ensuring the safety of transfusion and blood-derived products. *Transfusion Medicine and Hemotherapy*; **47**(2): 89-95.
- Zhang, X., et al. (2020). Mass spectrometry for structural characterization of therapeutic antibodies. *Mass Spectrometry Reviews*; **39**(5-6): 662-680.

Citation: Dunya, Y.*, Bukar, A., Obi, S.O., Medugu, J.T., Waziri, N.S., John, W.K., Mela, T.S., Halima, I., Azuike, C.G. Preparation of Plasma-based Medicinal Products in Combating Coagulation Factors Deficiencies by Apheresis Technique. *Sokoto Journal of Medical Laboratory Science*; **10**(1): 406–412. <https://dx.doi.org/10.4314/sokjmls.v10i1.38>

Copyright: This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.